Biogen discontinues first Alzheimer’s drug, goes all-in on Leqembi

Biogen is officially pivoting away from Aduhelm, the first Alzheimer’s treatment the Cambridge drugmaker made. Biogen said over the past year it looked for potential partners or external financing for Aduhelm, but neither materialized.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks